Cautious Report Unlikely To Slow Partial-Breast Irradiation Market, Firms Say
This article was originally published in The Gray Sheet
Executive Summary
In its most recent assessment of accelerated partial-breast irradiation (APBI), the BlueCross BlueShield Association Technology Evaluation Center reiterated that APBI as the sole radiation treatment following breast-conserving surgery for early stage cancer has not been proven beneficial. But companies in the budding APBI market say the report does not deter them from marketing or developing their treatments (see chart: "1FDA-Cleared APBI Devices ")